What is the latest published MRK stock rating?

Merck & Co., Inc. is shown with Hold in the latest published report, analyzed 2026-09-08. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MRK analysis?

The full latest published report, analyzed 2026-09-08, lives at /stocks/MRK/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for MRK?

The latest published report analyzed 2026-09-08 gives MRK a fair value of USD 141 and a potential value of USD 279. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the MRK page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-08). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

MRK Stock: Fundamentals & Analysis | StockMarketAgent.AI

Войти Start free

Merck & Co., Inc. (MRK)

NYSE: MRK · USD

—

StockMarketAgent Research · Analyzed 2026-09-08

Our latest published analysis: MRK rated Hold

Merck & Co., Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$141 / share

Potential value

$279 / share

Upside to FV

-6.0%

Moat

1/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$370.9B
P/E (forward)	15.7x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 15.7x
Market cap: $370.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$48.70B	$59.28B	$60.12B	$64.17B	$65.01B	+7.5%
Gross profit	$35.08B	$41.87B	$43.99B	$48.98B	$46.73B	+7.4%
Operating income	$14.69B	$17.41B	$3.04B	$21.21B	$22.42B	+11.2%
Net income	$13.05B	$14.52B	$365.0M	$17.12B	$18.25B	+8.8%
EPS (diluted)	$5.14	$5.71	$0.14	$6.74	$7.28	+9.1%
EBITDA	$17.90B	$21.32B	$6.91B	$25.71B	$28.26B	+12.1%
R&D	$12.25B	$13.55B	$30.53B	$17.94B	$15.79B	+6.6%
SG&A	$9.63B	$10.04B	$10.50B	$10.82B	$10.73B	+2.7%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	—	—	—	—	—	—	Продавать
ABT	Abbott Laboratories	—	—	—	—	—	—	Сокращать
ACN	Accenture plc	—	—	—	—	—	—	Держать
ALGN	Align Technology Inc.	—	—	—	—	—	—	Сокращать
ALNY	Alnylam Pharmaceuticals, Inc.	—	—	—	—	—	—	Активно покупать
AMGN	Amgen Inc.	—	—	—	—	—	—	Покупать

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($141.37). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
4.6%	$176	$195	$223	$268	$352
5.6%	$146	$156	$169	$187	$214
6.6%	$127	$133	$141	$150	$163
7.6%	$114	$118	$122	$128	$135
8.6%	$104	$107	$110	$114	$118

Scorecard

Published factor rows and weighted composite

Valuation4.5

Management6.5

Balance Sheet5.0

Profitability5.0

Revenue Growth6.0

Risk Assessment7.0

Competitive Moat1.0

Earnings Quality4.5

Capital Efficiency7.5

Weighted composite

5.2/10

Mixed

Category	Score	Reading
Valuation	4.5
Management	6.5
Balance Sheet	5.0
Profitability	5.0
Revenue Growth	6.0
Risk Assessment	7.0
Competitive Moat	1.0
Earnings Quality	4.5
Capital Efficiency	7.5

История рейтингов

Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.

Год	янв.	февр.	март	апр.	май	июнь	июль	авг.	сент.	окт.	нояб.	дек.
2026

Merck & Co., Inc. (MRK)

Our latest published analysis: MRK rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · MRK

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on MRK

Frequently asked questions

История рейтингов